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Antibiotic therapy is a causative agent of severe disturbances in microbial communities.
In healthy individuals, the gut microbiota prevents infection by harmful microorganisms
through direct inhibition (releasing antimicrobial compounds), competition, or stimulation
of the host’s immune defenses. However, widespread antibiotic use has resulted in
short- and long-term shifts in the gut microbiota structure, leading to a loss in colonization
resistance in some cases. Consequently, some patients develop Clostridium difficile
infection (CDI) after taking an antibiotic (AB) and, at present, this opportunistic pathogen
is one of the main causes of antibiotic-associated diarrhea in hospitalized patients. Here,
we analyze the composition and functional differences in the gut microbiota of C. difficile
infected (CDI) vs. non-infected patients, both patient groups having been treated with AB
therapy. To do so we used 16S rRNA gene and metagenomic 454-based pyrosequencing
approaches. Samples were taken before, during and after AB treatment and were checked
for the presence of the pathogen. We performed different analyses and comparisons
between infected (CD+) vs. non-infected (CD−) samples, allowing proposing putative
candidate taxa and functions that might protect against C. difficile colonization. Most
of these potentially protective taxa belonged to the Firmicutes phylum, mainly to the
order Clostridiales, while some candidate protective functions were related to aromatic
amino acid biosynthesis and stress response mechanisms. We also found that CDI
patients showed, in general, lower diversity and richness than non-infected, as well as
an overrepresentation of members of the families Bacteroidaceae, Enterococcaceae,
Lactobacillaceae and Clostridium clusters XI and XIVa. Regarding metabolic functions,
we detected higher abundance of genes involved in the transport and binding of
carbohydrates, ions, and others compounds as a response to an antibiotic environment.
Keywords: Gut microbiota, bacterial composition, metabolic functions, C. difficile infection, colonization
resistance
INTRODUCTION
The human intestinal microbiota is involved in many host func-
tions, such as food processing, regulating intestinal epithelium
growth, immune system development, synthesis of essential vita-
mins, or protection against pathogens (Hooper et al., 2002;
Guarner and Malagelada, 2003; Hattori and Taylor, 2009; Leser
and Mølbak, 2009; Montalto et al., 2009). Because of its role in
human health, imbalances in the gut microbiota have been associ-
ated to pathologies such as inflammatory bowel disease, diabetes,
obesity, or Crohn’s disease (Kang et al., 2010; Sekirov et al., 2010;
Morgan et al., 2012; Shanahan, 2013). Antibiotic (AB) therapy has
been crucial to treat bacterial infections for over half a century,
but it strongly disturbs the gut commensal bacteria and, con-
sequently, the beneficial functions they perform (Jernberg et al.,
2010; Willing et al., 2011; Pérez-Cobas et al., 2013a). In fact, AB
usage has been associated to short and long-term changes in the
intestinal microbiota, reducing colonization resistance to oppor-
tunistic pathogens such as Clostridium difficile (Vollaard and
Clasener, 1994; Bartlett, 2002; Jernberg et al., 2010; Reeves et al.,
2011; Britton and Young, 2012). C. difficile is an anaerobic, spore-
forming, Gram-positive toxin-producing bacterium, which is the
most common cause of nosocomial diarrhea, and broad spectrum
ABs constitute one of the primary risk factors for infection by
this pathogen (Hookman and Barkin, 2009; Cohen et al., 2010).
Under normal conditions, the human gut microbiota is able to
prevent pathogen invasion through general mechanisms such as
direct inhibition (by releasing inhibitory compounds, bacteri-
ocins), nutrient depletion (consuming growth-limiting nutrients)
or stimulating host immune defenses (reviewed in Stecher and
Hardt, 2011). The exact mechanism by which the microbiota pro-
tects against C. difficile infection (CDI), preventing its growth
and virulence, is still unknown. In this regard, direct antagonism
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was found in vitro since C. difficile is a target of bacteriocin pro-
duced by an intestinal strain of Bacillus thuringensis (Britton and
Young, 2012). Since the gut microbiota participates actively in
the fermentation of diet carbohydrates, amino acid and lipid
metabolism and protein digestion, Theriot et al. used a metabolic
model of CDI in mice and found that ABs affect all these func-
tions, leading to a disturbed microbiota functional state that
favors C. difficile germination and growth (Theriot et al., 2014).
Moreover, gut microorganisms participate in bile acid transfor-
mation, which otherwise stimulate C. difficile spore germination
and growth (Britton and Young, 2012). Thus, the loss of key
taxa which play these roles can trigger a structural and func-
tional imbalance, allowing colonization by this opportunistic
pathogen.
In recent years, high-throughput molecular techniques, such
as 16S rRNA gene sequence analyses (taxonomic composition
of microbial communities), metagenomics (genetic potential
of microbial communities) and other meta-“omics” (metatran-
scriptomics, metaproteomics, metabolomics) have extended our
knowledge of intestinal microbiota diversity and functions (Gill
et al., 2006; Kurokawa et al., 2007; Zoetendal et al., 2008; Tap et al.,
2009; Gosalbes et al., 2011; Pérez-Cobas et al., 2013a,b). Some of
these approaches have recently been used to address the effects of
ABs in the gut ecosystem (Dethlefsen et al., 2008; Antonopoulos
et al., 2009; Dethlefsen and Relman, 2010; Jakobsson et al., 2010;
Antunes et al., 2011; Pérez-Cobas et al., 2013b) showing that
ABs considerably alter the gut microbial ecology and the host-
microbiota interactions (Pérez-Cobas et al., 2013a). The response
of the microbiota to ABs is related to properties of the agent,
such as the antimicrobial effect, mode of action, dosage and dura-
tion of treatment, or route of administration (Jernberg et al.,
2010; Pérez-Cobas et al., 2013b). In addition, biological factors of
the host-microbial ecosystem itself such as taxonomic and func-
tional composition, resistance gene reservoir, or host immune
homeostasis also contribute to the microbial community shifts
associated to AB therapy (Jernberg et al., 2010; Willing et al.,
2011; Relman, 2012). To date, few studies have aimed to ascer-
tain whether specific changes in the microbiota composition due
to AB therapy lead to CDI. Past surveys have shown that diver-
sity of the intestinal microbiota is significantly reduced in patients
prior and/or during CDI, as well as important structural changes
associated to infection (Antharam et al., 2013; Vincent et al.,
2013).
The main goal of the present follow-up study is to gain
insights into the development of CDI and its relation to an
altered human gut microbiota. We have used 16S rRNA gene and
metagenomic approaches to characterize the structure and func-
tions of the intestinal microbiota before, during and after broad
spectrum AB therapy in patients who developed CDI. In two pre-
vious studies we explored the effect of broad spectrum ABs on
human gut microbiota composition and function in patients that
did not develop CDI at any time (Pérez-Cobas et al., 2013a,b).
Comparative analyses of these two groups of patients identified
bacterial taxa and metabolic functions associated to an infection
status, as well as specific taxa and functions that could pro-
tect against the C. difficile, and thus contribute to colonization
resistance of the human gut microbiota.
MATERIALS AND METHODS
SAMPLE COLLECTION
Three patients under AB therapy at the Department of Internal
Medicine of the University Hospital Schleswig-Holstein, Kiel,
Germany were recruited for the study due to the fact that they
were positive for C. difficile at some time points of the treat-
ment. The patients were older than 65 years, no antibiotic ther-
apy was administered to them in the previous 6 months to
their hospital admission. The diagnosis at the entrance to the
hospital were ischaemic colitis, sigmoid diverticulitis and infec-
tion of unknown origin for patients referred as F, G, and H,
respectively. The patients stayed in the hospital during the AB
therapy. Written, informed consent was obtained from all the
subjects.
Fecal samples were collected, before, during and after AB treat-
ment, from the three patients in sterile tubes and stored at−80◦C
until processing all sample together. Fecal samples were screened
by multiplex PCR for C. difficile toxin genes, tcdA and tcdB, and
triose phosphate isomerase gene (tpi), considering C. difficile pos-
itive those samples that resulted positive for the three examined
genes (referred as CD+, whereas CD− is used for the rest of
samples). Patients F and H were found positive after 16 and
35 days after AB treatment, respectively, whereas patient G was
found positive on entering hospital (Table 1). The three patients
presented diarrhea during AB theraphy.
In two previous studies we evaluated the effect of broad-
spectrum antibiotics on five patients (A, B, C, D, E) through
similar approaches of those presented in this work (16S rRNA
gene and metagenomics) as part of the same research sur-
vey (Pérez-Cobas et al., 2013a,b) that was approved by the
Ethical Committee of the University Hospital Schleswig-Holstein.
None of these patients developed CDI (they were negative for
the multiplex PCR for C. difficile tcdA, tcdB, and tpi genes),
or presented diarrhea. The main features and therapy of all
patients (A, B, C, D, E, F, G and H) are shown in Table 1.
Only the time-points used in this study are shown for the
patients A, B, C, D, and E (all CD− samples) of the previous
studies.
DNA EXTRACTION AND SEQUENCING PROCESS
The fecal samples were resuspended in sterile PBS [contain-
ing, per liter, 8 g of NaCl, 0.2 g of KCl, 1.44 g of Na2HPO4,
and 0.24 g of KH2PO4 (pH 7.2)] and centrifuged at 1250 g
and 4◦C for 2min to remove fecal debris. The supernatants
were centrifuged at maximum speed at 4◦C for 5min to pel-
let the cells. DNA was extracted with the QIAamp® DNA Stool
Kit (Quiagen) following the manufacturer’s instructions. Total
DNA integrity was checked by running a standard agarose gel
electrophoresis and the concentration was quantified with the
QuantiT PicoGreen dsDNA Assay Kit (Invitrogen). For each sam-
ple, except of F_after from which there was no enough amount of
DNA, the total DNA (metagenome) was directly pyrosequenced
with a Roche GS FLX sequencer and Titanium chemistry in
the Center for Public Health Research (FISABIO-Salud Pública)
(Valencia, Spain). Thus, a total of 12 metagenomes were analyzed.
We obtained a mean of 78,976 reads per sample with an average
length of 374 bp.
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Table 1 | Description of the patients involved in the study.
Patient Antibiotic Sampling date Samples code Study CD (+/−)
A Moxifloxacin Day0—before AB A_before Pérez-Cobas et al., 2013b −
Day3—during AB A3_D −
Day6—during AB A6_D −
Day10—during AB A10_D −
Day13—during AB A13_D −
B Clindamycin Day0—before AB B_before Pérez-Cobas et al., 2013b −
Day2—during AB B2_D −
Day5—during AB B5_D −
Day6—during AB B6_D −
C Cefazolin/Ampicillin/Sulbactam Day0—before AB C_before Pérez-Cobas et al., 2013b −
Day3—during AB C3_D −
Day6—during AB C6_D −
Day10—during AB C10_D −
D Amoxicillin Day0—before AB D_before Pérez-Cobas et al., 2013b −
Day3—during AB D3_D −
E Ampicillin/Sulbactam/Cefazolin Day0—before AB E_before Pérez-Cobas et al., 2013a −
Day3—during AB E3_D −
Day6—during AB E6_D −
Day11—during AB E11_D −
Day14—during AB E14_D −
F Amoxicillin/Ciprofloxacin/Clarithromycin Day0—before AB F_before Present study −
Day16—during AB F16_D +
3 days after AB F_after +
G Ciprofloxacin Day0—before AB G_before Present study +
Day4—during AB G4_D +
4 days after AB G_after +
H Vancomycin/Ampicillin/Sulbactam Day0—before AB H_before Present study −
Day7—during AB H7_D −
Day14—during AB H14_D −
Day20—during AB H20_D −
Day35—during AB H35_D +
Day38—during AB H38_D +
26 days after AB H_after −
CD (+/−), positive and negative detection for C. difficile. AB, antibiotic.
16S rRNA GENE AMPLIFICATION
A region of the 16S rRNA gene (V1, V2, and V3) was amplified by
polymerase chain reaction (PCR) for each sample. The primers
were the universal E8F (5′-AGAGTTTGATCMTGGCTCAG-3′)
with adaptor A and 530R (5′-CCGCGGCKGCTGGCAC-3′) with
adaptor B using the sample-specific Multiplex Identifier (MID)
for pyrosequencing according to 454 standard protocols. For
each sample a 50µl PCR mix was prepared, containing 5µl of
Buffer Taq (10X) with 20mM MgCl2, 2µl of dNTPs (10mM),
1µl of each primer (10mM), 0.4µl of Taq Fast start poly-
merase (5 u/µl), 39.6µl of nuclease-free water and 1µl of DNA
template. PCR conditions were: 95◦C for 2min followed by 25
cycles of 95◦C for 30 s, 52◦C for 1min and 72◦C for 1min
and a final extension step at 72◦C for 10min. The amplifica-
tion products were checked by electrophoresis in agarose gel
(1.4%). PCR products were purified using NucleoFast® 96 PCR
Clean-Up Kit (Macherey-Nagel) and quantified with the QuantiT
PicoGreen dsDNA Assay Kit (Invitrogen). The pooled PCR prod-
ucts were directly pyrosequenced in the same way as the total
DNA (described above). We obtained an average of 5394 reads
per sample.
ANALYSIS OF THE 16S rRNA GENE READS
We used the Ribosomal Database Project (RDP) pipeline (Cole
et al., 2009) to trim off the MID and primers and also to fil-
ter sequences by quality. Sequences with a phred quality score
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below 20 (Q20) and short length (<250 bp) were discarded. The
denoising of the sequences was performed with the usearch pro-
gram in the QIIME pipeline (Caporaso et al., 2010). Then, the
pyrosequencing chimeras were discarded using the uchime filter-
ing also in the QIIME pipeline. After, OTUs were calculated at
97% of sequence similarity by clustering with the usearch pro-
gram in the QIIME pipeline. The taxonomic assignment of the
amplicons was based on the database of RDP. We included only
annotations obtained with a confidence level (bootstrap cut-off)
greater than 0.8, leaving the assignment at the last-well identified
level and the consecutive levels as unclassified (uc).
BIODIVERSITY AND ECOLOGICAL ANALYSIS
To analyze the microbial community structure at OTU level
(97%) we calculated two diversity parameters: number of OTUs
and Shannon index (Shannon, 1948) and two richness estima-
tors: Chao1 (Chao, 1984) and abundance-based coverage (ACE)
(Chao et al., 2000). These estimators are implemented in Vegan
package (Oksanen et al., 2011) under R software (http://cran.
r-project.org) (R Development Core Team, 2011). To statistically
compare the mean ranks of the biodiversity measures between
groups, we used the Wilcoxon signed-rank test implemented in
the R software.
We also performed a clustering based on OTU composition
to study the similarity between samples using the pvclust library
(Suzuki and Shimodaira, 2006) in the R software. This analy-
sis assesses the uncertainty in hierarchical clusters using boot-
strap resampling techniques.We used the approximately unbiased
(AU) p-value with 10,000 bootstraps to estimate the probability
of each cluster. This AU p-value indicates how strong the cluster
is supported by data.
FUNCTIONAL CLASSIFICATION OF METAGENOMES
We used the 454 Replicate Filter Program (Gómez-Alvarez et al.,
2009) to eliminate artifact replicate reads of pyrosequencing fol-
lowing the parameters: sequence identity cutoff= 1; length differ-
ence requirement= 0; number of beginning base pairs to check=
10. Reads were compared against the human genome database
using BLASTN (Altschul et al., 1990) with an e-value of 10−10
to eliminate possible contamination with human sequences. To
identify the sequences encoding the ribosomal 16S rRNA and 23S
rRNA genes we compared the dataset against the Small Subunit
rRNA Reference Database (SSUrdb) and the Large Subunit rRNA
Reference Database (LSUrdb) described in Urich et al. (2008)
using BLASTN with an e-value of 10−16 and 10−4 respec-
tively. After removing the ribosomal genes, the remaining reads
were compared to the NCBI-nr protein database using BLASTX
(Altschul et al., 1990) to identify the protein-coding genes, and
then we performed an Open Reading Frames (ORFs) search with
the Fraggenscan program from the metagenomic analysis web
server (WebMGA) (Wu et al., 2011). The predicted ORFs were
functionally annotated by HMMER 3.0 (Durbin et al., 1998)
against the TIGRFAM database (Haft et al., 2003) using default
parameters.
STATISTICAL ANALYSIS
Canonical correspondence (CCA) and detrended correspondence
(DCA) analyses were performed to explore the relationship
between different groups of samples and with C. difficile infec-
tion as a variable that could explain the variability pattern.
To statistically assess the effect of that variable in explaining
the bacterial composition differences, a multivariate ANOVA
based on dissimilarity tests (Adonis) was applied, implemented
in the Vegan package under the R software. These approaches
were applied to two different levels: the taxonomy based on
the 16S rRNA gene, and the biological functions based on the
TIGRFAMs annotations. We used the ShotgunFunctionalizeR
package (Kristiansson et al., 2009) in the R software to sta-
tistically compare samples at diversity and functional levels.
The differences in composition between samples were addressed
comparing groups of multiple samples with the function “test-
GeneFamilies.dircomp.” On the other hand, we applied the
“testGeneCategories.dircomp” function to compare the distri-
bution of functional categories between groups of samples. It
compares each gene family from a higher functional category
to decide whether the global category is statistically significant
among two groups of samples. All tests were based on Poisson
models.
SEARCHING FOR PUTATIVE CANDIDATE TAXA AND METABOLIC
FUNCTIONS TO PROTECT AGAINST CDI
We also used the “testGeneCategories.dircomp” test to identify
taxa and metabolic functions that could play a protective role
against C. difficile colonization. Specifically, we performed three
comparisons between groups of samples to identify taxa and
functions that were significantly over-represented in CD− com-
pared to CD+ samples. The taxa and functions resulting from
the different comparisons were intersected to define the candidate
protective group. For this purpose, we performed the following
comparisons:
Comparison 1.Since patients F and H were negative to
the pathogen before treatment but positive during therapy,
we compared the CD− samples before AB (F_before and
H_before) against the CD positive samples (CD+) during AB
(F_16D, H35_D and H38_D) (Table 1). We aimed to iden-
tify taxa and functions that significantly decreased (p-value
< 0.1) due to treatment, presumably allowing C. difficile
overgrowth.
Comparison 2. Since patients A, B, C, D and E did not develop
CDI, we performed a comparison of the samples before AB treat-
ment against their samples during treatment (Table 1). We aimed
to identify taxa and functions that significantly increased (p-value
< 0.1) due to therapy or that changed less drastically than those in
Comparison 1, since their presence could play a role in preventing
C. difficile infection.
Comparison 3. Since patient H was negative for the pathogen
26 days after AB, we carried out a comparison of the CD+
samples of patient H (H35_D and H38_D) against the CD−
sample taken after AB (H_after) (Table 1). We aimed to identify
taxa and functions whose significant increase (p-value < 0.05)
could be incompatible with pathogen overgrowth as this was not
detected.
Finally, we intersected all these results to obtain a group of
candidate taxa and functions that could participate in C. difficile
colonization resistance.
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CO-OCCURRENCE BAYESIAN NETWORKS OF CANDIDATES (TAXA AND
METABOLIC FUNCTIONS) IN CD− SAMPLES
To find positive correlations between candidate protective taxa
or functions found in the previous analyses and other taxa and
functions obtained for samples from patients A, B, C, D and E
during AB treatment (all CD− samples), we performed Bayesian
networks based on their relative abundance. The Bayesian net-
works were inferred using the bnlearn package (Scutari, 2010)
in the R software. The optimal network inference was con-
strained so that only those interactions exhibiting a Spearman
correlation p-value below 0.01 were included in the network.
Correlations and p-values were computed using the Spearman
method implemented in R software.
DATA ACCESSION NUMBER
All sequences have been entered in the European Bioinformatics
Institute database, under accession numbers: ERP002192
(patients A, B, C, and D), ERP001506 (patient E) and PRJEB5771
(patients F, G, and H).
RESULTS
MICROBIAL DIVERSITY AND BACTERIAL COMPOSITION IN PATIENTS
DEVELOPING CDI
Analysis of the gut microbiota of the three CDI patients (F, G,
and H) showed large variations in bacterial composition during
therapy (Figure 1).
Before AB treatment, the bacterial composition of patient
F was dominated by the Akkermansia genus (30.6%) belong-
ing to the family Verrucomicrobiaceae. Other bacterial fam-
ilies were also abundant such as Ruminococcaceae (20.8%),
Oscillibacteriaceae (Oscillibacter, 11.7%) and Bacteroidaceae
(Bacteroides, 14.8%). When C. difficile was detected, at day 16 of
AB treatment, all these taxa were almost absent in the commu-
nity except Bacteroides, which had increased to 41.9%, becoming
a predominant genus of the gut ecosystem. The Clostridium clus-
ter XlVa increased dramatically (from 0.7% before AB course
to 46.8% at day 16), being the most abundant group at this
time point. After treatment, the abundance of the main taxa
of the microbial community changed again, the predominant
being Enterococcaceae (Enterococcus, 48.3%), Streptococcaceae
(Streptococcus, 43.2%), Staphylococcaceae (Staphylococcus, 4.1%)
and Clostridium cluster XI (3.5%).
Patient G was found positive to C. difficile detection before,
during, and after AB treatment, showing the most simi-
lar bacterial composition at the three time points, though
there are some remarkable differences. The initial composi-
tion (G_before) consisted mostly of Bacteroidaceae (Bacteroides,
36.7%) and Ruminococcaceae (Faecalibacterium, 29.6%). During
AB (G4_D), although Bacteroides decreased in abundance to 25%,
it remained the most abundant genus, while Faecalibacterium
(5.9%) decreased radically. However, Enterococcus increased dur-
ing AB (from 1.3 to 14.9%). After therapy (G_after), Clostridium
cluster XI became the predominant group (62.4%) whereas
Streptococcus genus decreased progressively at each time point (3,
2.2, and 0.2%, respectively).
Patient H had a very unusual gut microbiota before AB treat-
ment, being dominated (85.7%) by Enterobacteriaceae family,
mainly Escherichia genus, but its abundance decreased dramati-
cally reaching the lowest values at days 35 and 38 of the broad-
spectrum AB treatment (4.2 and 2.8%, respectively), when C.
difficile was detected. During days 7 and 14 of AB treatment
the genus Bacteroides showed the higher abundance values (20.4
and 34.8%); however this taxon decreased on day 20, becoming
undetectable by days 35 and 38. Streptococcus genus increased
slightly in the two CD+ samples (1.5 and 4.5%, respectively).
The most striking shift occurred in the Lactobacillaceae family
(Lactobacillus genus), whose frequency increased from less than
1% at the beginning of treatment to 83.3 and 70% on days 35
and 38 of the AB course, and was reduced to 15.5% after AB. We
performed a statistical comparison to evaluate the differences in
bacterial composition between the samples immediately prior to
C. difficile detection (H14_D, H20_D) and in the CD+ samples
(H35_D, H38_D). (Table S2). The main significantly overrepre-
sented taxa were Lactobacillus, Streptococcus, Proteus, Sutterella
and the uc_Lactobacillaceae, while the Clostridium cluster XlVa,
Enterococcus, Bacteroides, Escherichia, Klebsiella, and Roseburia
were the least abundant taxonomic groups.
The three individuals exhibited great fluctuations in the
number of observed OTUs, as well as in the diversity parameters
analyzed (Table S1). The diversity (based on Shannon, Chao
1 and ACE estimators) of patient F was reduced in the CD+
samples, being minimal after the therapy. The microbial diversity
of patient G also reached the lowest values after treatment. The
decreased diversity after the course in these two patients could
be due to both, the AB and CDI effects. However, the patient H,
which was recovered of the infection after the therapy, presented
the lowest diversity parameters before the AB that could be due to
the massive presence of members of the Enterobacteriaceae
family detected in this sample and also during CDI
(Figure 1).
Finally, we performed a cluster analysis to find similari-
ties in microbiota composition between samples at OTU level
(97%) (Figure 2). The three samples corresponding to patient G
(G_before, G4_D and G_after) were clustered with F_after, being
all CD+ samples. This cluster was closer to the others two sam-
ples of patient F (F_before and F16_D). Patient H samples formed
two clear groups. One of the clusters included the prior infection
samples (before AB and 7, 14 and 20 days during AB) whereas the
CD+ samples (days 35 and 38), which are the most similar sam-
ples, grouped in a second cluster with the sample after treatment
(H_after). The clustering shows that both the individual and the
C. difficile presence contributed to explain the similarity pattern
of the samples.
DIFFERENCES IN MICROBIAL STRUCTURE BETWEEN
C. DIFFICILE -INFECTED AND NON-INFECTED PATIENTS
In previous studies we analyzed changes in bacterial composition
in AB-treated patients that did not develop C. difficile infection
(A, B, C, D and E), and thus all samples were CD−. To search for
differences in microbiota composition possibly related to infec-
tion, we compared the 15 time points during the AB therapy of
these CD− patients with samples from patients that were positive
for C. difficile detection (CD+) (F16_D, F_after, G_before, G4_D,
G_after, H35_D and H38_D) (Table 1).
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FIGURE 1 | Fecal microbiota composition in CDI patients (F, G, and H). The composition of each sample is based on the RDP taxonomic assignment of the
16S rDNA sequences. The phylum and the genus level are shown for the most abundant bacterial groups (>5%).
FIGURE 2 | Cluster analysis based on OTUs (97%) of CDI patients (F, G,
and H). The approximate unbiased (AU) p-values are shown.
First, we compared the Shannon index distributions between
CD+ and CD− samples (Figure S1). We found a lower diversity
for CD+, with an average of 3.1 ± 1.0 compared to CD− sam-
ples with 3.9 ± 0.8, respectively. The richness estimator, Chao1,
showed great variations for both groups; even so, the means were
also lower in the CD+ populations with values of 210 ± 132 vs.
287 ± 157 in CD− individuals. The Wilcoxon signed-rank test
was performed to compare the diversity measures between both
groups, and was not significant for the Shannon index (p = 0.14)
and the Chao1 estimator (p = 0.33). The gut microbiota of CD+
samples seems to be more heterogeneous and less rich than the
CD− samples corresponding to patients that did not develop
CDI, but a larger number of samples would be required to
support this observation.
Second, we performed a detrended correspondence analysis
(DCA) to explore the variations in bacterial composition between
the same CD+ and CD− samples tested above (Figure 3A).
The two axes explained 26. 7% of the total variance, and there
was large variability in the microbiota of both groups. Despite
this variability, two clusters can be distinguished with minimal
overlapping. We applied the Adonis test to evaluate whether
developing C. difficile infection is a factor that influences the
microbiota structure. The factor proved to be significant with a
p-value of 0.005.Thus, although the CD+ samples do not form a
well-defined cluster, they share some features in their microbiota
composition that differ from CD− samples.
Finally, we performed a statistical test to find those taxa
that explained the differences in composition between CD−
and CD+ groups. In CD+ samples there was significant
over-representation of the genera Lactobacillus, Bacteroides,
Enterococcus, Faecalibacterium, the family Lachnospiraceae incer-
tae sedis, and the Clostridium clusters XIVa and XI, the lat-
ter included C. difficile. However, commensal members of the
intestinal community, such as Roseburia, Coprococcus, Blautia, or
Subdoligranulum genera and the families Erysipelotrichaceae and
Ruminococcaceae were underrepresented (Table 2).
CANDIDATE TAXA INVOLVED IN C. DIFFICILE COLONIZATION
RESISTANCE
In order to obtain a subset of candidate bacteria that could
be involved in C. difficile colonization resistance, we per-
formed statistical comparisons between different groups of
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FIGURE 3 | Correspondence analyses. (A) Detrended correspondence
analysis (DCA) based on taxa abundance and composition of CD+ samples of
patients (F, G, and H) (red square) and CD− samples of patients (A, B, C, D,
and E), during treatment (blue square). Gray triangle indicates taxa
distribution. (B) Correspondence analysis (CA) based on the functional profile
(TIGRFAMs) of the same samples. Gray triangle indicates functions.
Table 2 | Differential taxa abundance between CD− (during time
points of A–E patients) and CD+ (F16_D, F_after, G_before, G4_D,
G_after, H35_D and H38_D) samples.
Taxa Abundance in CD+ samples P-value
Clostridium cluster XlVa Increase 0
Clostridium cluster XI Increase 0
Lactobacillus Increase 0
Bacteroides Increase 0
Lachnospiracea incertae sedis Increase 5.65E-137
Faecalibacterium Increase 2.30E-121
Enterococcus Increase 7.06E-120
uc_Lachnospiraceae Decrease 0
Blautia Decrease 0
uc_Ruminococcaceae Decrease 0
uc_Enterobacteriaceae Decrease 0
Roseburia Decrease 0
Parabacteroides Decrease 0
Subdoligranulum Decrease 0
Oscillibacter Decrease 0
Coprococcus Decrease 2.01E-84
Alistipes Decrease 1.78E-46
uc_Erysipelotrichaceae Decrease 8.51E-54
Butyricicoccus Decrease 1.18E-48
Lactococcus Decrease 1.62E-46
Streptococcus Decrease 0.01
samples (see Materials and Methods for the three specific
comparisons). The three comparative analyses gave a num-
ber of statistically significant taxa (Table 3), and intersec-
tion of the results of the three analysis indicated which
taxa may participate in colonization resistance to C. diffi-
cile. We found that the major number of taxa belonged to
the order Clostridiales (Firmicutes), specifically to the fam-
ilies Ruminococcaceae (Ruminococcus, Subdoligranulum, and
Gemmiger), Oscillibacteraceae (Oscillibacter) and Eubacteriaceae
(Anaerovorax). We also found unclassified Ruminococcaceae
and Erysipelotrichaceae belonging to the Clostridiales and
Erysipelotrichales orders, respectively, as well as other Clostridia
and Clostridiales members. Finally, the genus Escherichia from
the family Enterobacteriaceae, Proteobacteria phylum, was also
detected.
Once the candidate protective taxa had been detected, we
performed a Bayesian network (see Materials and Methods)
to find other related members of the bacterial community
and hence also putatively involved in pathogen coloniza-
tion resistance (Figure 4). Gemmiger, Subdoligranulum and uc_
Erysipelotrichaceae did not show any significant correlation and
thus they are not represented in the figure. It is worth noting that
most taxa showing a positive and significant correlation with the
candidates were phylogenetically related to them, mainly belong-
ing to the Clostridiales order, such as Roseburia and Coprococcus
(Lachnospiraceae family) and Anaerotroncus (Ruminococcaceae
family).
FUNCTIONAL CHANGES IN PATIENTS DEVELOPING CDI
In the present work, we performed the functional annotation of
the 12 metagenomes sequenced (metagenome of sample F_after
could not be analyzed, seeMaterials andMethods) by comparison
against the TIGRFAM database, obtaining the following hierar-
chical classification: main roles (the highest functional level), sub
roles (more specific metabolic functions for each one of the main
roles) and genes (metabolic functions) for all the reads. Figure
S2 shows great homogeneity in the main role distribution of dif-
ferent samples for all three patients (F, G, and H). On average,
the most abundant main role categories were: energy metabolism
(12.3% ± 2.1), protein synthesis (12% ± 2), transport and bind-
ing proteins (8.6± 2.5%) and cell processes (8.6± 1.3%). Similar
main role distribution was described for patients A, B, C, and
D in our previous study (Pérez-Cobas et al., 2013b), which is
expected due to the importance of these household functions for
the survival and growth of gut bacteria.
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Table 3 | Significant taxa and associated p-value resulting from the
three comparative analyses to find protective candidate taxa.
Taxa Comparison Comparison Comparison
1(a) 2(b) 3(c)
Akkermansia 0 1.66E-4 NS
Anaerotruncus 4.62E-6 NS NS
Anaerovorax 1.12E-70 1.43E-3 3.41E-3
Clostridium cluster IV 6.11E-14 NS 1.27E-32
Clostridium cluster XlVb 0.02 NS NS
Clostridium cluster XVIII 2.16E-18 6.44E-73 NS
Enterococcus 2.63E-7 2.62E-258 NS
Erysipelotrichaceae
incertae sedis
1.46E-6 1.23E-6 NS
Escherichia 0 6.48E-22 6.01E-12
Faecalibacterium 6.71E-5 NS NS
Gemmiger 0.07 0.05 3.41E-3
Holdemania 0.07 1.52E-11 NS
Oscillibacter 0 1.33E-15 8.23E-42
Pseudoflavonifractor 5.42E-16 NS NS
Pyramidobacter 0.04 NS NS
Ruminococcus 4.85E-228 1.19E-6 5.25E-10
Subdoligranulum 1.03E-19 2.76E-8 3.41E-3
uc_Clostridia 1.62E-3 4.27E-5 3.46E-5
uc_Clostridiales 2.35E-11 0.06 1.57E-18
Clostridiales incertae
sedis XIII
1.62E-3 0.04 NS
uc_Enterobacteriaceae 3.18E-6 1.73E-17 NS
uc_Erysipelotrichaceae 0.02 0.07 3.46E-5
uc_Ruminococcaceae 0 7.85E-117 4.44E-129
Anaeroglobus NS NS 1.47E-33
Bacteroides NS NS 5.85E-11
Dialister NS NS 5.25E-10
Selenomonas NS NS 4.73E-9
uc_Betaproteobacteria NS NS 0.04
uc_Lachnospiraceae NS NS 1.50E-9
In bold are the candidate taxa that were significant in the three comparisons.
(a) (F_before and H_before) vs. (F_16D, H35_D, and H38_D).
(b) A, B, C, D, and E samples before vs. during AB treatment.
(c) (H35_D and H38_D) vs. (H_after).
In patient F, there were 51 significantly different sub
roles between samples corresponding to before and during
AB treatment (F_before vs. F16_D) (Table S3). The most
significant over-represented categories in AB treated samples
were: DNA metabolism/chromosome-associated proteins; cellu-
lar processes/DNA transformation; cell envelope/biosynthesis and
degradation of surface polysaccharides and lipopolysaccharides;
and energy metabolism/ pentose phosphate pathway. The under-
represented categories were: protein synthesis/tRNA aminoacyla-
tion; transport and binding proteins/amino acids; peptides and
amines; and cell envelope/surface structures.
Three different comparisons were made for patient H: (i)
before vs. during treatment but before C. difficile detection
(H_ before vs. H7_D, H14_D and H20_D); (ii) before vs. CD+
samples (H_before vs. H35_D and H38_D) and (iii) CD− prior
FIGURE 4 | Bayesian network of microbial composition in CD−
samples of patients (A–E), during treatment, and the candidate
protective taxa. The significant positive correlations (p-value < 0.01)
between the candidate protective taxa and other members of the bacterial
community are shown. The correlation coefficients are indicated. Gray and
white nodes represent candidate and correlated taxa, respectively.
Candidate taxa with no-correlations are not included.
to CDI vs. CD+ samples (H14_D and H20_D vs. H35_D and
H38_D). In total, we found 37 significant sub roles increased
or decreased in CD− samples. (i) Those that increased dur-
ing AB but before CDI were mainly involved in “cell pro-
cesses/DNA transformation” and “protein synthesis/translation
factors,” whereas we observed a significant decrease in “amino
acid biosynthesis/folic acid”; “mobile and extrachromosomal ele-
ments function/plasmid functions”; “signal transduction/PTS”
and “transport and binding proteins/carbohydrates, organic alco-
hol and acids.” (ii). A similar functional profile was found
when we compared before vs. CD+ samples. (iii) Finally, when
we specifically compared the two samples previous to infec-
tion with the two CD+ samples we found 54 significant sub-
roles. The most significant over-represented in the CD+ samples
were: “signal transduction/PTS”; “transport and binding pro-
teins/carbohydrates, organic alcohols, and acids”; “transport and
binding proteins/amino acids, peptides and amines” and “cell
envelope/biosynthesis and degradation of mureinsacculus and
peptidoglycan” (Table S3).
Patient G proved to be infected by the pathogen through-
out the study. Thus, we compared the sub roles distribu-
tion, before vs. during treatment, to find those functions that
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could be AB-related. The comparison showed that only two
categories changed during AB: “amino acid biosynthesis/serine
family” decreased (p = 0) while “cell envelope/other” increased
(p = 0.04).
DIFFERENCES IN THE FUNCTIONAL PROFILE BETWEEN
C. DIFFICILE -INFECTED AND NON-INFECTED PATIENTS
To compare the whole functional composition of CD+ sample
of patients F, G, and H with CD− samples during treatment of
patients A, B, C, D, and E, we applied a correspondence anal-
ysis based on TIGRFAM functions abundance, with both axes
explaining a total of 49.3% of sample variance. The analysis did
not show a clear differential functional pattern between the CD+
and CD− groups given the CD+ samples seem to be a subset of
the CD− group (Figure 3B). We also used the Adonis test to eval-
uate the significance of ABs in structuring the functional profile
of the microbial community in a different way for the two groups
(CD+ and CD−). The factor was not significant at the hierar-
chical level sub roles and metabolic functions, the p-values being
0.63 and 0.73, respectively. To find specific sub roles that could be
associated to CD+ samples, we compared the functional profile
of the same previously tested samples (Table 4), finding signifi-
cant enrichment in “transport and binding proteins,” mainly for
“carbohydrates, organic alcohols and acids,” and “signal transduc-
tion” by the phosphotransferase system (PTS). However, “mobile
and extrachromosomal element functions” and “aromatic amino
acid family biosynthesis” were significantly underrepresented.
CANDIDATE FUNCTIONS INVOLVED IN C. DIFFICILE COLONIZATION
RESISTANCE
Just as in the 16S rRNA gene survey, we performed three com-
parative analyses to find (in the intersection) those metabolic
functions that may play a role in colonization resistance. Table 5
shows the roles, sub roles, and functions that may be protec-
tive. Those with a clearly assigned role are involved in “aromatic
amino acid biosynthesis (chorismate mutase),” “endospore for-
mation (stage IV sporulation protein B and anti-sigma F factor),”
“metabolism of amino groups (agmatine diminase),” and “stress
response mechanisms (rrf2 family protein, redox-active disul-
fide protein 2 and glutamate decarboxylase).” Doubled CXXCH
domain belongs to a protein of unknown function but it is
postulated to be part of c-type cytochromes that participate
in electron transfer. UDP-N-acetylglucosamine 4,6-dehydratase
participates in the biosynthesis of pseudaminic acid. No sub-roles
were assigned to indolepyruvate ferredoxin oxidoreductase and
RNA polymerase sigma-70 factor.
We also performed a Bayesian network to find significant and
positive associations between the candidate protective functions
and other functions that may be important in pathogen infec-
tion resistance. Figure 5 shows the functional network according
to hierarchical categories. In a general overview, most of the can-
didate functions were connected with several different sub roles,
and correlations between candidates were also found. The most
frequently connected function was the doubled CXXCH domain
(26 correlations), and chorismate mutase (25 correlations).
Additionally, these two candidate functions shared some connec-
tions whose nodes are involved in different roles, the majority
Table 4 | Comparisons of sub-roles distribution between CD− (during
time points of A–E patients) and CD+ (F16_D, F_after, G_before,
G4_D, G_after, H35_D and H38_D) samples.
Main role Sub-role P-value
Amino acid biosynthesis Aromatic amino acid family ↓1.5E-29
Biosynthesis of
cofactors, prosthetic
groups, and carriers
Pantothenate and coenzyme A ↓8.2E-7
Riboflavin, FMN, and FAD ↑1.2E-2
Cellular processes DNA transformation ↓1.0E-3
Sporulation and germination ↓1.2E-2
Toxin production and
resistance
↓4.9E-3
Central intermediary
metabolism
Amino sugars ↑2.0E-6
One-carbon metabolism ↑2.3E-2
Other ↑3.9E-6
Phosphorus compounds ↓6.0E-4
Sulfur metabolism ↓8.6E-3
DNA metabolism Chromosome-associated
proteins
↑6.1E-8
Degradation of DNA ↓1.4E-2
DNA replication,
recombination, and repair
↑1.1E-2
Restriction/modification ↓1.0E-3
Energy metabolism Electron transport ↓1.7E-3
Fermentation ↑3.0E-4
Glycolysis/gluconeogenesis ↑1.6E-4
Pentose phosphate pathway ↑1.5E-2
Sugars ↑2.3E-2
Hypothetical proteins Conserved ↓9.4E-7
Mobile and
extrachromosomal
element functions
Other ↓3.4E-17
Protein synthesis Other ↑4.7E-2
tRNA and rRNA base
modification
↑8.2E-3
Purines, pyrimidines,
nucleosides, and
nucleotides
2′-Deoxyribonucleotide
metabolism
↓1.4E-2
Purine ribonucleotide
biosynthesis
↑3.6E-7
Salvage of nucleosides and
nucleotides
↑3.0E-4
Regulatory functions Protein interactions ↓3.6E-5
Signal transduction PTS ↑1.5E-20
Transcription Degradation of RNA ↑1.5E-3
DNA-dependent RNA
polymerase
↑1.5E-2
RNA processing ↑8.2E-3
(Continued)
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Table 4 | Continued
Main role Sub-role P-value
Transport and binding
proteins
Anions ↑9.5E-4
Carbohydrates, organic
alcohols, and acids
↑6.3E-18
Cations and iron carrying
compounds
↑1.2E-5
Unknown substrate ↑3.6E-5
Unknown function General ↑2.0E-6
Arrows indicate the sub-roles significantly over-represented (upward) and under-
represented (downward) in the CD+ samples.
Table 5 | Candidate functions involved in C. difficile colonization
resistance.
Main role Sub-role Function
Amino acid
biosynthesis
Aromatic amino acid
family
Chorismate mutase
Cellular processes Sporulation and
germination
Stage IV sporulation
protein B
Regulatory functions Protein interactions Anti-sigma F factor
Central intermediary
metabolism
Polyamine
biosynthesis
Agmatine deiminase
Unknown function General rrf2 family protein
Redox-active
disulfide protein 2
NA NA Glutamate
decarboxylase
Doubled CXXCH
domain
Indolepyruvate
ferredoxin
oxidoreductase
RNA polymerase
sigma-70 factor*
UDP-N-
acetylglucosamine
4,6-dehydratase
*RNA polymerase sigma-70 factor, Bacteroides expansion family 1.
being related to energy metabolism, protein synthesis and fate, as
well as amino acid biosynthesis. The UDP-N-acetylglucosamine
4,6-dehydratase showed 21 correlations, mainly with cell enve-
lope, protein fate and transport system roles. Also, this func-
tion was connected to another important candidate: glutamate
decarboxylase, with which it shares some correlations. The redox-
active disulfide protein 2 and glutamate decarboxylase presented
17 correlations each. The former, which is correlated to the
two candidates known as chorismate mutase and indolepyru-
vate ferredoxin oxidoreductase, showed associations with energy
metabolism and protein synthesis, while glutamate decarboxy-
lase is correlated to protein fate, regulatory and transport
functions.
DISCUSSION
In this study, we have analyzed changes in the bacterial
composition and functional profile of the gut microbiota of two
patients (F and H) that were positive for C. difficile (CD+ sam-
ples) after AB treatment and one patient (G) that despite not
having taken AB was already CD+ when entered to the hos-
pital. Patients F and H had an unusual microbiota at the start
of the study (before AB treatment), enriched in Akkermansia
genus (30.6%) and highly abundant in Escherichia genus (85.7%),
respectively. We also compared the gut microbiota of those three
patients with five individuals from two previous studies (Pérez-
Cobas et al., 2013a,b), who were also treated with AB but did
not develop CDI. All the patients fit the same inclusion crite-
ria. Despite the heterogeneity of the samples and only 15 time
points are overall compared, we consider that the results obtained
with the different analyses performed, provide new insights into
the effect of CDI on the structure and metabolic functions of the
human gut microbiota. Furthermore, we identified members of
the bacterial community and metabolic functions that are dif-
ferentially present in the CD− samples compared to the CD+
samples and thus could be involved in resistance to C. difficile
colonization.
The gut microbiota of the three CDI patients showed large
variations in bacterial composition and diversity throughout the
therapy, confirming that antibiotics disturb the ecological equi-
librium of microbial communities. Previous studies showed great
fluctuations and low diversity of the human gut microbiota under
the effects of a wide variety of ABs, although patients did not
develop CDI (Dethlefsen et al., 2008; Dethlefsen and Relman,
2010; Pérez-Cobas et al., 2013a,b). In addition to the influence of
AB on the microbiota structure, this survey found that CDI con-
tribute to decreasing bacterial diversity since the infected samples
showed, in general, lowest biodiversity index values and richness
estimators than non-infected samples. In this respect, a mouse
colitis model-based study has suggested that intestinal inflamma-
tion during colonization by some pathogens, includingC. difficile,
affect microbiota equilibrium (reviewed in Stecher and Hardt,
2011), contributing to reduced microbial diversity.
Similarly, significant alterations in the abundance of some taxa
(mainly from the Firmicutes phylum) and a decrease in microbial
diversity and species richness were found in individuals with CDI
(Antharam et al., 2013).
We have found that the microbiota of the infected samples
(CD+) share some common features, being depleted in commen-
sal genera such as Ruminococcus, Roseburia, Subdoligranulum,
Blautia orCoprococcus and enriched in Lactobacillus, Enterococcus,
Clostridium clusters XlVa and XI. The latter being the phyloge-
netic cluster which contains the C. difficile species (Collins et al.,
1994). Although the relative abundance of cluster XI was variable
between the infected samples, its presence is higher in CD+ than
in CD− samples, probably due to the high abundance of C. dif-
ficile. The higher abundance of Clostridium cluster XIVa could
be a consequence of the microbiota imbalance, since members
of this group have been characterized as opportunists (Lozupone
et al., 2012). This may also be the case of Enterococcus, which is
a common opportunistic pathogen that becomes dominant when
the normal gut microbiota is disturbed by ABs (Donskey, 2004;
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FIGURE 5 | Bayesian network of microbiota potential functions in CD−
samples of patients (A–E), during treatment, and the protective
candidate taxa. The significant positive correlations (p-value < 0.01)
between the candidate protective functions and other functions of the gut
ecosystem are shown. Each node represents a specific function with the
corresponding subrole color. The candidate protective function nodes are
indicated by numbers: (1) Chorismate mutase; (2) Stage IV sporulation
protein B; (3) Anti-sigma F factor; (4) Agmatine deiminase; (5) rrf2 family
protein; (6) Redox-active disulfide protein 2; (7) Glutamate decarboxylase; (8)
Doubled CXXCH domain; (9) Indolepyruvate ferredoxin oxidoreductase; (10)
RNA polymerase sigma-70 factor, Bacteroides expansion family 1; (11)
UDP-N-acetylglucosamine 4,6-dehydratase.
Ubeda et al., 2010). Enterococcus was also over-represented in
samples of reduced biodiversity in other CDI studies (Antharam
et al., 2013; Vincent et al., 2013). The higher abundance of
Lactobacillus in the CD+ samples is also interesting. For example,
a murine model-based study found that Lactobacillaceae was
dominant in CDI samples (Rea et al., 2011) as did a study of
CDI in humans (Antharam et al., 2013). Although Lactobacillus
has been described as an intestinal probiotic genus, different
studies show that only specific strains (e.g., L. delbrueckii) can
inhibit C. difficile growth (Naaber et al., 2004; Banerjee et al.,
2009). Further research would be needed to clarify the role of
Lactobacillus strains in gut colonization by C. difficile.
The three comparisons performed enabled us to identify
taxa that were significantly over-represented in CD− sam-
ples, due to AB therapy, in individuals that either did not
develop CDI (comparison 2) or recover from CDI (comparison
3), but decreased in those CD+ samples (Comparison 1).
Thus, Anaerovorax, Escherichia, Gemmiger, Oscillibacter,
Ruminococcus, Subdoligranulum, uc_Clostridia, uc_Clostridiales,
uc_Erysipelotrichaceae, and uc_Ruminococcaceae were found
as candidates for protecting against C. difficile colonization.
Bayesian correlation networks are a powerful tool to search and
study ecological or metabolic associations in microbial commu-
nities (Durbán et al., 2012), and thus we used them to look for
other taxa associated to the above, which may be also indirectly
involved in resistance by ecologically interacting with the can-
didates. Most of the taxa in the network belonged to Clostridia:
Ruminococcus, Subdoligranulum, Oscillibacter, Anaerovorax,
Roseburia, Coprococcus, Anaerotroncus, Gemminger and other
unclassified members of Lachnospiraceae and Ruminococcaceae
families. It has been proposed that competition of normal gut
microbiota members with their related pathogens for limiting
resources or sites, called “niche exclusion,” could be a coloniza-
tion resistance mechanism (reviewed in Britton and Young,
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2012). Thus, this niche hypothesis could explain the role of these
related taxa belonging to Clostridiales in protecting against CDI.
In this regard, some studies in mice have shown that Clostridia
members, such as Lachnospiraceae, are C. difficile antagonists
and restore the microbiota when fed to infected mice (Itoh et al.,
1987; Reeves et al., 2011, 2012; Lawley et al., 2012). Another
study in hamsters showed that non-toxigenic C. difficile were
able to prevent the toxigenic pathogen (Sambol et al., 2002;
Merrigan et al., 2003), suggesting a more efficient utilization of
limiting nutrients (niche exclusion) as the protection mecha-
nism. In human studies, members of the Ruminococaceae and
Lachnospiraceae families were significantly depleted in CDI
patients (Antharam et al., 2013).
Some of the Clostridia members found to be associated to the
main protective candidate taxa, such as Roseburia or Coprococcus,
are active anaerobic short-chain fatty acids (SCFA) producers
(Barcenilla et al., 2000; Pryde et al., 2002). This could be other
mechanism through they are candidates to protect against CDI,
since SCFA are reported to inhibit C. difficile growth and also
to decrease the production of toxin in vitro (May et al., 1994).
Moreover, it has been postulated that the anaerobic fraction of
the microbiota is essential for gut ecosystem stability in healthy
individuals, because the butyrate and other SCFAs they produce
have anti-inflammatory effects and stimulate the immune system
and, thus, this imbalance increases the risk of C. difficile over-
growth (Bartlett, 2002; Roy et al., 2006; Jernberg et al., 2010).
However, a recent study in mice found that SCFA production was
no correlated with lower levels of C. difficile colonization (Reeves
et al., 2012). In addition, these authors found that the micro-
biota composition of CDI mice was partially restored when they
used only one isolate of the Lachnospiraceae family for inocula-
tion. Nevertheless, total restoration was obtained when total fecal
content was transferred from a wild-type mouse. These results
agree with our findings because we have found several putative
candidate protective taxa, indicating that more than one bac-
terial group is involved in pathogen protection. Hence, further
research should test in vivo the colonization resistance capacity of
the specific ensemble we have proposed.
In a previous study, we showed that the metabolic profiles of
AB-associated shifts in human gut microbiota were less dramatic
than those in bacterial composition, principally when considering
main roles. This is due to functional redundancy of the human
gut microbiota, and the fact it has a very general set of functions
(Pérez-Cobas et al., 2013b). We have also found great homogene-
ity in distribution of the main role in all the samples. However,
differences appear when considering more inclusive functional
levels (sub-roles and functions). In this study, patients showed
different functional responses (sub-roles) to ABs, in agreement
with our previous study where a great inter-individual variability
was found in AB-treated patients. Although no significant dif-
ferences between both groups of AB-treated patients (CDI and
non-infected) as a whole were detected, a specific functional
profile was found. Thus, the transport, metabolism, and regu-
lation of sugars such as mannose, fructose, lactose, glucitol, or
mannitol were over-represented functions in CDI samples, the
major sugar transport system being the phosphotransferase sys-
tem (PTS). In a previous work, we found that AB increases PTS
in metagenomes, since it seems to give advantage to bacteria
carrying them under stress conditions (Deutscher et al., 2006;
Pérez-Cobas et al., 2013b). The higher presence of these functions
in CD+ samples compared to CD− is noteworthy, even when
both were treated with ABs, because it could be related with the
infection, as shown in a metabolomic study in mice that devel-
oped CDI (Theriot et al., 2014). The same authors found an
increase in carbohydrates like mannose, fructose, lactose, gluci-
tol, or mannitol after AB treatment, and they postulated that these
increases favored C. difficile germination and growth. Related to
this finding, a transcriptomic study revealed that sugars released
by an altered microbiota are exploited by enteric pathogens such
as Salmonella enterica and C. difficile (Ng et al., 2013). Thus, C.
difficile and other opportunistic bacteria can efficiently catabolize
the excess of carbohydrates generated by the disruptedmicrobiota
and, in the absence of competitors, increase colonization rates.
Using the same three comparisons, we also found metabolic
functions that may play a role inC. difficile colonization resistance
(Table 5). Overall, there was a higher abundance of functions
related to aromatic amino acid biosynthesis, being chorismate
mutase the central node of the network, since it was strongly
connected to other important functions like energy metabolism
or protein fate. The chorismate mutase, which participates in
tyrosine, phenylalanine and tryptophan biosynthesis, could be
involved in colonization resistance through stimulation of the
immune system, since the tryptophan metabolite participates
in immune system equilibrium and inflammation regulation
(Zelante et al., 2013). Future research should be conducted to
discover the mechanism by which aromatic amino acid synthe-
sis could protect against colonization by C. difficile. Also, some
energy metabolism pathways seem important, such as TCA cycle,
electron transport, or fatty acid biosynthesis. A great number of
different transporter families, regulator genes, and genes involved
in responses to osmotic or acid stress were also highlighted in the
network, possibly playing a role in colonization resistance.
Another possible protective pathway was peptide catabolism
via tryptophan metabolism. Low abundance of protein digestion
markers was associated to susceptibility to CDI in the mouse
gut (Theriot et al., 2014). Regarding host immune response,
we found polyamine biosynthesis (putrescine or cadaverine) by
decarboxylation of amino acids to be another potential protec-
tive pathway. A previous study reported that these metabolites
interact with the gut microbiota, stimulating the immune sys-
tem and playing a role in intestinal maturation (Gómez-Gallego
et al., 2012). In this regard, Jung et al. (2003) found that glu-
tamate decarboxylase activity, related to polyamines, was also
a protective determinant, playing a role in protection against
acid stress. It is also relevant that this enzyme is connected
to other functions in the network, such as protein fate, tran-
scription regulation, or transport systems, thus reinforcing its
protective role. Moreover, other protective gene-products regu-
late metabolic pathways that are important for several cellular
physiology processes, like osmotic stress resistance and responses
to environmental changes (Wouters et al., 2010; Shepard et al.,
2011).
In summary, we found specific fecal microbiota in CDI
patients as it was enriched in Lactobacillus, Enterococcus,
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Clostridium clusters XIVa and XI but depleted in SCFA-
producing bacteria. The latter bacterial group could be involved
in C. difficile colonization resistance. A group of metabolic
processes related to the metabolism of proteins, amino acids
and responses to stress would seem to participate in avoiding
pathogen invasion in the human gut ecosystem. Further research
into these pathways should be undertaken to unravel the mech-
anism by which they participate in colonization resistance to C.
difficile. A larger cohort of patients with similar sampling would
be needed to deeper define the CDI microbiota at taxonomic and
functional level.
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